A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

NCT07688148 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Cancers

Interventions

DRUG: TAX2

Sponsor

Apmonia Therapeutics